Results
from a prospective case-control
study’‘
We read with great interest the recently published article by
Selntigia et al. 1 The paper concludes that patients with
co-occurrence of both endometriosis and migraine
(EM-MG) have higher pain intensity compared to patients
with endometriosis only (EM-O) or migraine only
(MG-O) and also the patients with both endometriosis
and migraine has more severe gynaecological in filtrations
compared to endometriosis only patients. However, we
have several concerns regarding the overly assertive con-
clusions, methodology, and statistical and power analysis
of the study.
One primary issue is the study’s broad strokes in conclud-
ing that EM-MG patients suffer from more severe endometri-
osis/adenomyosis compared to those with endometriosis
alone. This simpli fication overlooks the complexity of
disease severity and the distinct classification systems for ade-
nomyosis and deep in filtrating endometriosis (DIE). By
equating the presence of adenomyosis or DIE with “more
severe gynecological infiltrations” without a systematic com-
parison of endometrioma, DIE, and other lesions, the study
fails to accurately capture disease severity. Furthermore, the
similar frequency of DIE and endometrioma between the
EM-MG and EM-O groups undermines the claim of inher-
ently greater disease severity in the comorbid group, espe-
cially without a comparative analysis of severity.
Secondly, the study ’s emphasis on the signi ficance of
the CGRP pathway is notable, yet it may overextend its con-
clusions. The increased pain intensity observed in patients
with both endometriosis and migraine, as opposed to those
with just one condition, can be attributed to a variety of
factors including hormonal changes, chronic in flammation,
altered pain sensitivity, genetic factors, psychological distress,
fatigue, and both peripheral and central sensitization, along
with delayed diagnosis and treatment
2. Therefore, focusing
extensively on the CGRP pathway and asserting its targeting
efficacy without direct pathophysiological evidence might
exceed the study’s scope and be overly conclusive.
Thirdly, while the study points to a relationship between
increased migraine pain scores and speci fic endometriosis
subtypes (DIE and adenomyosis), it lacks direct correlation
analysis to substantiate this association.
The study ’s methodology also presents several notable
issues. Initially, the approach is hindered by sampling
bias due to its observational design and patient recruitment
from two distinct departments: endometriosis and head-
ache. The selection criteria for patients with both endomet-
riosis and migraine (EM-MG) lack clarity, particularly
regarding their initial clinic of presentation. This oversight
introduces potential biases, as symptoms and severity
reported by EM-MG patients could be skewed based on
whether they first sought treatment at the endometriosis or
headache clinic. Furthermore, treatment biases may exist;
EM-only patients not receiving hormonal treatments
likely represent milder cases, while the hesitancy of clini-
cians to use hormonal treatments in EM-MG patients, espe-
cially those with migraine with aura, might mean this group
disproportionately represents more severe endometriosis
cases. Additionally, the study ’s protocol speci fies that
each EM-MG case was matched with two control patients
from each of the EM-O and MG-O cohorts based on a
strict BMI matching criterion of ±1 unit range. However,
the actual reported mean BMI differences between the
EM-MG group and the control groups exceed this thresh-
old, with variations of up to 2 BMI units. This variation
indicates a deviation from the described matching process
and raises concerns about the study ’s methodological
adherence and the reliability of its comparative analysis.
Lastly, the study ’s power analysis is compromised due
to the absence of an effect size, crucial for assessing the
ability to identify meaningful differences, and incorrectly
employing the Kruskal-Wallis test for two-group compari-
sons. Moreover, the statistical analysis presents concerns,
as demonstrated by mean VAS scores (inherently non-
negative) having standard deviations larger than the
means, indicating a non-normal distribution. This issue
raises concerns about the appropriateness of utilizing
t-tests for data analysis, suggesting a need for non-
parametric tests or methods such as logarithmic transforma-
tions to ensure a normal distribution for precise analysis.
In conclusion, while this study contributes to the under-
standing of the comorbidity between endometriosis and
migraine, these concerns highlight the need for cautious
Creative Commons Non Commercial CC BY -NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and dis-
tribution of the work without further permission provided the original work is attributed as speci fied on the SAGE and Open Access page (https://us.
sagepub.com/en-us/nam/open-access-at-sage).
Letter to the Editor
Cephalalgia
2024, Vol. 44(5) 1 –2
© International Headache Society 2024
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/03331024241254824
journals.sagepub.com/home/cep
interpretation of the findings and call for further research to
address the complex relationship between these conditions
more comprehensively.
References
1. Selntigia A, Exacoustos C and Ortoleva C et al. Correlation between
endometriosis and migraine features: Results from a prospective
case-control study. Cephalalgia 2024; 44: 3331024241235210.
2024/03/04. DOI: 10.1177/03331024241235210.
2. Morotti M, Vincent K and Becker CM. Mechanisms of pain
in endometriosis.European Journal of Obstetrics & Gynecology
and Reproductive Biology 2017; 209: 8 –13. DOI: 10.1016/j.
ejogrb.2016.07.497.
Utku AKGOR 1 and Onur INCE 1
1Department of Obstetrics and Gynecology, 64005Faculty
of Medicine, Hacettepe University, Ankara, Turkey.
Corresponding authors:
Utku Akgör, Department of Obstetrics and Gynecology,
Faculty of Medicine, Hacettepe University, 06230 Ankara,
Turkey. Email: + 905495197799
2 Cephalalgia 44(5)